publication date: Jul. 26, 2019

Lung Ambition Alliance seeks global partners to double lung cancer survival rates by 2025

By Matthew Bin Han Ong

The recently formed Lung Ambition Alliance seeks to double the five-year survival rate for lung cancer—up to 40%, by 2025.

Founding members of the alliance that was rolled out in London July 8 are: the International Association for the Study of Lung Cancer, the Global Lung Cancer Coalition, Guardant Health, and AstraZeneca. Other organizations in oncology and public health are encouraged to join, the founders say.

“We believe that, as has been done previously in the breast cancer field, we are looking at creating a solid alliance that is completely open to additional partners,” IASLC President Giorgio V. Scagliotti, head of the Department of Oncology and professor of medical oncology at the University of Torino in Italy, said to The Cancer Letter. “We believe that is the only way to move forward, as we see it.”

The goals include improving prevention, screening and treatment, offer education, collect data to validate regulatory endpoints, and fund innovative research. Founders didn’t specify the amount of money that has been committed or the amount sought.

“The genesis story for the alliance really stems back to that daunting statistic that one in five people with lung cancer will be alive after five years, and understanding that statistic—what it means for the population, for people afflicted with disease,” IASLC CEO Dave Mesko said to The Cancer Letter. “We thought bringing the talents of pharma, diagnostic companies, advocacy groups, and a scientific society together would give us a nice platform for those diverse perspectives and allow us to really come at this challenging question, this issue, from multiple facets, multiple angles, from … Continue reading Lung Ambition Alliance seeks global partners to double lung cancer survival rates by 2025

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.